Pune, India -- (SBWIRE) -- 04/17/2018 -- Data Bridge Market Research report provides an extensive analysis of current and future market status of the "Global Radiopharmaceuticals Market" for purchase this report mail us at firstname.lastname@example.org Or call on number +1-888-387-2818
"Global Radiopharmaceuticals Market" is expected to reach USD 9.49 billion by 2024 from USD 4.87 billion in 2016, at a CAGR of 8.7% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Click Here for Free Sample Report Visit @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-radiopharmaceuticals-market
Recent Developments: Radiopharmaceuticals Market
Recent trends in the radiopharmaceuticals market such as growing disease which targeted cancer therapy, increasing awareness, expanding applications of molecular imaging, technological advancement, increasing trend of radio-labelled peptides and monoclonal antibodies for the diagnosis and treatment of cancer tumors and increasing use of SPECT & PET scans is expected to drive the market in the forecast period 2017 to 2024.
Radiopharmaceuticals are mostly used for treatment of cancer, bone pain, and thyroid cancer. In the U.S. cancer is second fatal disease whereas in the UK it is the leading cause of death. In most of the third world countries cancer appears much lower. Cancer is the second leading cause of death globally and was responsible for 8.8 million deaths in 2015. Globally, nearly 1 in 6 deaths is due to cancer. In 2016, an estimated 1.6 million new cases of cancer was diagnosed in the United States and 0.5 million people died from the disease.
On the other hand, shorter half-life of radiopharmaceuticals, stringent regulatory guidelines and competition from conventional diagnostic procedures are some of the factors which may hinder the growth of radiopharmaceuticals market.
Any Specific Requirements? Questions? Ask to Our Industry Expert @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-radiopharmaceuticals-market
The global market is segmented based on type, procedural volumes, application, sources, end-user, and geography.
On the basis of type, the global radiopharmaceuticals market is sub-segmented into
- Therapeutic radiopharmaceuticals.
In 2017, diagnostic radiopharmaceuticals segment dominate the market and is expected to grow at the highest in the forecast period. This is due to the production of MO-99 in the U.S., FDA approvals of radiopharmaceuticals, initiatives of International Atomic Energy Agency (IAEA), new irradiation facility in Germany, installation of PET scanners in India, andgovernment investments in Rest of Asia-Pacific.
On the basis of procedural volumes, the global radiopharmaceuticals market is sub-segmented into
1. Diagnostic procedure
- single-photon emission computed tomography (SPECT) radiopharmaceuticals
- positron emission tomography (PET) radiopharmaceuticals
2. Therapeutic procedures
- beta emitters
- alpha emitters
- brachy therapy
On the basis of application, the global radiopharmaceuticals market is sub-segmented into
1. diagnostic application
- single-photon emission computed tomography (SPECT) -
- positron emission tomography (PET)- oncology, cardiology, neurology and others
2. therapeutic application
- bone metastasis,
- endocrine tumours
On the basis of sources, the global radiopharmaceuticals market is sub-segmented into
- nuclear reactors
On the basis of end user, the global radiopharmaceuticals market is sub-segmented into
- ambulatory surgical centers,
- diagnostic centers,
- cancer research institutes and
In 2017, hospital segment dominate the market with the highest market share due to accessibility of highly skilled medical practitioners in the radiology departments of hospitals.
Questions? We'll Put You On The Right Path Request Analyst Call @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-radiopharmaceuticals-market
TABLE OF CONTENTS
1.1. OVERVIEW OF THE GLOBAL RADIOPHARMACEUTICALS MARKET
1.2. CURRENCY AND PRICING
1.4. MARKETS COVERED
2 MARKET SEGMENTATION
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE GLOBAL RADIOPHARMACEUTICALS SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET TIME LINE
2.2.4 MARKET GUIDE
2.2.5 COMPANY POSITIONING GRID
2.2.6 COMAPANY MARKET SHARE ANALYSIS
2.2.7 MULTIVARIATE MODELLING
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 TOP TO BOTTOM ANALYSIS
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3. GLOBAL RADIOPHARMACEUTICALS MARKET: RESEARCH SNAPSHOT
3 MARKET OVERVIEW
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1. VENDOR POSITIONING GRID AND INVESTMENT OPPORTUNITIES
5.2. TECHNOLOLGICAL ADVANCEMENTS
5.3. INSIGHTS ON TECHNOLOGICAL DEVELOPMENTS IN THE GLOBAL RADIOPHARMACEUTICALSMARKET
5.4. MARKET REGULATORY SCENARIO BY COUNTRY
5.5. INTERVIEW KEY INSIGHTS
6 GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE
7 GLOBAL RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUMES
8 GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION
9 GLOBAL RADIOPHARMACEUTICALS MARKET, BY SOURCES
10 GLOBAL RADIOPHARMACEUTICALS MARKET, BY END-USER
11 GLOBAL RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY
12 GLOBAL RADIOPHARMACEUTICALS MARKET, COMPANY PROFILES
12.1 CARDINAL HEALTH INC.,
12.3 GE HEALTHCARE,
12.4 LANTHEUS MEDICAL IMAGING INC.,
12.5 BAYER AG,
12.6 COMPANY A
12.7 COMPANY B
12.8 COMPANY C
12.9 COMPANY D
12.10 COMPANY E
12.11 COMPANY F
10.12 COMPANY G
10.13 COMPANY H
10.14 COMPANY I
10.15 COMPANY J
10.16 COMPANY K
10.17 COMPANY M
10.18 COMPANY N
10.19 COMPANY O
12 ABOUT DATA BRIDGE MARKET RESEARCH
Request for Table of Content of Full Report @ http://databridgemarketresearch.com/toc/?dbmr=global-radiopharmaceuticals-market
Radiopharmaceuticals Market report give rising open doors in the market and the future effect of significant drivers and difficulties and, bolster leaders in settling on practical business choices. Radiopharmaceuticals are a group of pharmaceuticals drug which have radioactivity. It can be used as diagnostic and therapeutic agent. Radiopharmaceuticals are unique medicinal formulations containing radioisotopes which are used in major clinical area for diagnosis or therapy. The procedures and facilities for the production, use, and storage of radiopharmaceuticals are subject to licensing by national or regional authorities.
- Cardinal Health Inc.
- GE Healthcare
- Lantheus Medical Imaging Inc.
- Bayer AG
- Bracco Imaging SpA
- Eczacibasi-Monrol Nuclear Products
- Nordion Inc.
- Advanced Accelerator Applications S.A.
- IBA Molecular Imaging
- Actinium Pharmaceuticals Inc.,
- Among others.
Read more about Report Visit @ http://databridgemarketresearch.com/reports/global-radiopharmaceuticals-market/
North America Digital Health Monitoring Market – Industry Trends and Forecast to 2024
North America Digital Health Monitoring Market By Product Type Devices (Blood Pressure Monitors, Blood Glucose Monitors, ECG, Oximeters, Peak Flow Monitors, Multi Parameter Monitors, Sleep Neap Monitors, Neurological Monitors, Others), Software (Healthcare Apps, Chronic Disease Apps, Personal Health Apps, Others), Services (Remote Monitoring, Consultancy Services, Treatment Services, Fitness and Wellness Services, Others), By Country (U.S., Canada, Mexico) – Industry Trends and Forecast to 2024
Report Access: http://databridgemarketresearch.com/reports/north-america-digital-health-monitoring-devices-market/
About Data Bridge Market Research
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research